Contemporary narrative review of treatment options for COVID-19

Link to article at PubMed

Respirology. 2021 Jul 8. doi: 10.1111/resp.14106. Online ahead of print.


The coronavirus disease 2019 (COVID-19) pandemic is ongoing and many drugs have been studied in clinical trials. From a pathophysiological perspective, anti-viral drugs may be more effective in the early stage while immunomodulators may be more effective in severe patients in later stages of infection. While drugs such as lopinavir-ritonavir, hydroxychloroquine and azithromycin have proved to be ineffective in randomized controlled trials, corticosteroids, neutralizing monoclonal antibodies, remdesivir, tocilizumab and baricitinib have been reported to benefit certain groups of patients with COVID-19. In this review, we will present the key clinical evidence and progress in promising COVID-19 therapeutics, as well as summarize the experience and lessons learned from the development of the current therapeutics.

PMID:34240518 | DOI:10.1111/resp.14106

Leave a Reply

Your email address will not be published. Required fields are marked *